Cofoe Medical files HKEX next-day disclosure return on share repurchase for cancellationPUBT·Jul 28 at 04:50 AM01187-2.29%301087+2.33%
Hong Kong Mid-Caps Drive Summer Dealmaking Amid USD 2.3 Billion Bio-Licensing and Stock BuybacksGlobal Report·Jul 22 at 04:18 AM03692-0.49%01187-2.29%
The Strategic Divergence: When Real Estate Pivots to AI and Legacy Brands Seek New MoatsGlobal Report·Jul 15 at 04:14 AM01800-0.25%01798+1.59%
Hong Kong Healthcare and Industrials: RemeGen Advances as L.K. Tech Pivots to AI InfrastructureGlobal Report·Jul 9 at 09:02 PM09995+2.96%01187-2.29%
Pivots, Pitfalls, and the AI Mirage: Navigating Hong Kong's Fragmented 2026 MarketGlobal Report·Jul 9 at 05:03 AM03288-2.66%02338+7.58%
Cofoe Medical Technology Co. Ltd. Class H (1187) Receives a Buy from Exane BNP Paribasbusinessinsider·Jun 25 at 01:50 AM01187-2.29%
Brief News: COFOE MEDICAL's first listing fell nearly 6% in half a dayBambooWorks·May 6 at 12:31 AM01187-2.29%
COFOE passes the listing hearing: annual revenue of 3.4 billion, profit of 370 million, and the Zhang Min couple controls 54% of the equity雷帝触网·Apr 11 at 06:40 AM01187-2.29%301087+2.33%
Cofe Medical rushes to the Hong Kong stock market: annual revenue of 3.4 billion, profit of 370 million has obtained IPO filing雷帝触网·Mar 16 at 07:55 PM01187-2.29%
